Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Castle Biosciences Inc (CSTL)

Castle Biosciences Inc (CSTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation PR Newswire - Tue May 12, 6:00AM CDT

This marks the fifth MedTech Breakthrough Award that Castle has earned for its innovative testing solutions

CSTL : 18.63 (-2.15%)
Castle Biosciences Reports First Quarter 2026 Results PR Newswire - Wed May 6, 3:05PM CDT

Delivered Q1 2026 revenue of $83.7 million Q1 2026 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased...

CSTL : 18.63 (-2.15%)
Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month PR Newswire - Tue May 5, 6:00AM CDT

Longstanding   collaborations with   AIM at Melanoma, the Melanoma Research Foundation,   The   Skin Cancer Foundation, IMPACT Melanoma and The   Sun Bus continue to   advance...

CSTL : 18.63 (-2.15%)
New Data at DDW 2026 Show TissueCypher® Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barrett's Esophagus PR Newswire - Mon May 4, 6:00AM CDT

Clinical studies from Mayo Clinic researchers demonstrate the TissueCypher test provides improved risk stratification and influences risk-aligned surveillance decisions in clinical practice, with one study...

CSTL : 18.63 (-2.15%)
Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS PR Newswire - Tue Apr 21, 6:00AM CDT

Multi-center clinical and population-based data show that DecisionDx-Melanoma identifies biologically high-risk patients—including those with thin and early-stage disease—and provides recurrence risk...

CSTL : 18.63 (-2.15%)
Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026 PR Newswire - Wed Apr 15, 6:00AM CDT

FRIENDSWOOD, Texas , April 15, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will...

CSTL : 18.63 (-2.15%)
Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year PR Newswire - Fri Apr 10, 6:00AM CDT

FRIENDSWOOD, Texas , April 10, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has...

CSTL : 18.63 (-2.15%)
Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026 PR Newswire - Fri Mar 27, 8:05AM CDT

Data from 1,868 Surveillance, Epidemiology and End Results (SEER)-linked patients show DecisionDx-Melanoma significantly stratifies five-year melanoma-specific survival within American Joint Committee...

CSTL : 18.63 (-2.15%)
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB GlobeNewswire - Fri Mar 13, 10:02AM CDT

Among all patients studied, 2.6% nodal positivity and 97.8% three-year recurrence-free survival (RFS) was observed in those predicted to have less than 5% risk of a positive sentinel lymph node (SLN) by...

CSTL : 18.63 (-2.15%)
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk GlobeNewswire - Mon Mar 9, 6:00AM CDT

Study results were recently shared at the  Society of Surgical Oncology (SSO) 2026 Annual Meeting in Phoenix. NCCN Cutaneous Melanoma Guidelines recommend avoiding a sentinel lymph node (SLN) biopsy...

CSTL : 18.63 (-2.15%)

Barchart Exclusives

Inflation Has Pushed this Dividend Aristocrat to 52-Week Lows. Why It’s Still Not Quite Time to Buy. Barchart - Tue May 12, 6:30PM CDT
McDonald's stock is trading near its 52-week lows and has a dividend yield of aroudn 2.7%. However, the stock does not look like a compelling buy yet. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.